Abstract
12883 Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation versus treatment withdrawal with retreatment upon relapse in reSURFACE 1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have